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In this review, some of the challenges and opportunities encountered during protein
comparability assessments are summarized with an emphasis on developing new
analytical approaches to better monitor higher-order protein structures. Several case
studies are presented using high throughput biophysical methods to collect protein
physical stability data as function of temperature, agitation, ionic strength and/or solution
pH. These large data sets were then used to construct empirical phase diagrams
(EPDs), radar charts, and comparative signature diagrams (CSDs) for data visualization
and structural comparisons between the different proteins. Protein samples with
different sizes, post-translational modifications, and inherent stability are presented: acidic
fibroblast growth factor (FGF-1) mutants, different glycoforms of an IgG1mAb prepared
by deglycosylation, as well as comparisons of different formulations of an IgG1mAb and
granulocyte colony stimulating factor (GCSF). Using this approach, differences in structural
integrity and conformational stability profiles were detected under stress conditions that
could not be resolved by using the same techniques under ambient conditions (i.e.,
no stress). Thus, an evaluation of conformational stability differences may serve as
an effective surrogate to monitor differences in higher-order structure between protein
samples. These case studies are discussed in the context of potential utility in protein
comparability studies.
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INTRODUCTION TO COMPARABILITY ASSESSMENTS
Protein based drugs are structurally complex, highly specific
macromolecules used therapeutically to compensate for body
deficiencies (e.g., hormones and clotting factors), as medical
treatments (e.g., cytokines and monoclonal antibodies) as well
as to prevent diseases (e.g., polyclonal antiserum and certain
vaccines) (Aggarwal, 2012). A protein molecule’s structural com-
plexity makes it quite challenging to preserve biological activity
and stability throughout manufacturing, storage and adminis-
tration. Protein drug molecules are prone to different degrada-
tion mechanisms (chemical or physical) during manufacturing
and storage, which ultimately can lead to the loss of potency
(through structural alterations) as well as potentially increases
in immunogenicity reactions upon administration (Rosenberg,
2006; Murphy and Tsai, 2006; Weert and Møller, 2008; Manning
et al., 2010). Chemical degradation pathways involve covalent
bond modifications, as in Asn deamidation, Asp isomerization,
Met oxidation, polypeptide chain proteolysis and disulfide bond
shuffling (Manning et al., 2010). Physical degradation, on the
other hand, includes distinct pathways such as protein structural
alterations (Murphy, 1995), surface adsorption (Bee et al., 2011),
aggregation (Narhi et al., 2012) and precipitation (Wang, 2005).
There aremany causes leading to the physical and chemical degra-
dation of proteins including exposure to different environmental
stresses [e.g., agitation(Brych et al., 2010), UV light (Davies,
2003) and temperature (Banks et al., 2012)] as well as changes
in solution and formulation conditions [e.g., pH (Hari et al.,
2010), ionic strength (Majhi et al., 2006) and additives (Hamada
et al., 2009)]. A better understanding of the possible degradation
mechanism of a protein therapeutic is a key step in the formula-
tion development of safe and effective product candidates to be
evaluated in clinical trials.
Currently there are more than 150 protein-based drugs
approved by the FDA (1996) and EMA including ∼35 mono-
clonal antibodies (mAbs). In addition, more than 900 medicines
and vaccines are under clinical development, with 30mAb candi-
dates in late-stage trials (Aggarwal, 2012; Reichert, 2013). There
has been a concomitant increase in demand for more production
capacity to make larger amounts of protein drugs, challenging
manufacturers to develop new technologies and to scale-up their
manufacturing processes. The biopharmaceutical industry and
government regulators need an efficient and scientifically based
approach to evaluate the effect of process changes and produc-
tion scale-up on the structural integrity, physicochemical identity
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and clinical safety and efficacy of protein drug candidates. This
first led to the development of “well characterized biotechnology
products” and “comparability” regulatory guidance documents
in 1996. These general concepts of comparability were then fur-
ther defined and expanded by additional guidances from the
European Medicines Agency (EMA) in 2003 (Committee for
Proprietary Medicinal Products), the International Conference
on Harmonization (ICH) (Q5E) in 2003 (ICH Q5E, 2005) and
by the World Health Organization (WHO) in 2009 (Expert
Committee on Biological Standardization, 2009).
The primary and higher order structures of protein drug
molecules are delicate in nature, especially compared to small
molecule drugs, and are highly sensitive to environmental
changes and stresses in general. Changes in the manufacturing
process for a protein therapeutic may occur during clinical devel-
opment or after commercialization. These changes frequently
occur in either the manufacturing steps of the active drug sub-
stance (e.g., facility, equipment or process changes) or in the
finished drug product (e.g., formulation excipients, container-
closure system, dosage form changes) (Chirino and Mire-Sluis,
2004; Federici et al., 2013). The manufacturer may apply changes
in their manufacturing processes for variety of reasons such as
improving yields and purity, ensuring better patient convenience,
or facilitating compliance with new regulations. Comparability
studies are performed to assess the effect of these process and
product changes on the “critical quality attributes” (CQAs) by
comparing the pre and post-change protein products through
a series of tests performed in a head-to-head fashion. Critical
quality attributes are defined as the collective product qualities
defining the identity, purity, potency, safety and stability of the
protein drug product (ICH Q5E, 2005).
The assessment of comparability between the pre- and post-
change product relies on the ability to show experimentally the
samples are “highly similar” in terms of physiochemical and
biological characteristics, degradation profile, pharmacokinetics
and immunogenicity (ICH Q5E, 2005). Physiochemical charac-
terizations, biological assays and stability degradation profiles of
the drug product are considered the cornerstone of a compara-
bility exercise (Figure 1). The ability to establish highly similar
analytical profiles determines the need for additional animal
or clinical evaluations such as pharmacokinetic, efficacy and/or
immunogenicity studies (ICH Q5E, 2005).
PHYSIOCHEMICAL CHARACTERIZATION
Extensive physiochemical analytical characterization of the pre-
vs. post-change active pharmaceutical ingredient (i.e., protein
itself) and the final drug product (final dosage form including
protein, excipients, and primary container) is typically the first
step of a comparability evaluation. Peptide mapping is typically
the initial step, usually used to assess the integrity of the amino
acid residues and sequence within a specific protein molecule.
This technique involves the chemical or enzymatic treatment of
the protein to generate a specific set of peptide fragments, which
in turn are separated using reversed phase high performance
liquid chromatography (RP-HPLC) equipped with diode-array
ultraviolet (UV) for detection. Isolated peptide fragments are
also mass characterized using online mass spectrometry. Peptide
mapping has proven to be an especially valuable technique in
comparability studies, since each protein upon digestion with
specific proteolytic enzymes will give specific peptide fragments
that are used as a high resolution fingerprint for the protein
under evaluation (Skrlin et al., 2010; Lubiniecki et al., 2011;
Berkowitz et al., 2012; Li et al., 2013). Comparing the peptide
map profiles for the pre and post-change proteins can show
alterations in the protein polypeptide backbone such as frag-
mentation or changes in individual amino acid residues (e.g.,
mutation, oxidation, deamidation, or post-translational modifi-
cations). The correct disulfide pairing can also be evaluated using
the same technique by comparing peptides under reduced and
non-reduced conditions.
Various post-translational modifications (PTMs) such as
N-glycosylation, O-glycosylation and/or C-terminal lysine clip-
ping, are frequently observed upon changing the cell-culture
manufacturing processes. This is partially responsible for the
heterogeneous nature of pharmaceutical proteins, since they are
usually produced by cells in culture (Walsh and Jefferis, 2006).
Additionally, for glycoproteins, the nature of glycans and the
extent of glycosylation (e.g., erythropoietin is 40%N-glycosylated
vs. 2% N-glycosylation in an IgG1 monoclonal antibody) (Beck
et al., 2012) may be affected by process changes. Mass spec-
trometry based techniques are again frequently used to obtain
insight into a glycoprotein’s glycosylation pattern. Mass spec-
trometric ionization based techniques such as matrix-assisted
laser desorption/ionization (MALDI-MS) and electrospray ion-
ization (ESI-MS) are frequently used for this purpose (Zaia, 2008;
Brooks, 2009; Beck et al., 2012; Pompach et al., 2012; Desaire,
2013). A more detailed picture of the glycan structure and com-
position can be achieved using oligosaccharide mapping in which
the glycan residues are enzymatically cleaved from the protein and
then labeled with a fluorescent tag (e.g., 2-aminobenzamide is fre-
quently used) which is used for detection (Leymarie and Zaia,
2012; Bakovic´ et al., 2013).
Alterations in glycosylation patterns of proteins as a result
of manufacturing changes have been reported (Lubiniecki et al.,
2011). The role of glycosylation differences on the stability of
erythropoietin have also been investigated (Narhi et al., 1991).
Glycosylated erythropoietin was found to be more resistant to
denaturant and acidic pH induced unfolding compared to the
non-glycosylated form of the protein. Three intact IgG1mAbs
were compared before and after glycan removal using a variety
of analytical techniques (Zheng et al., 2011). An increase in flu-
orescence signal upon deglycosylation was observed indicating
structural perturbations, a conclusion that was further reinforced
by DSC results indicating a structural change in the CH2 region
of the IgG1mAbs. A similar study looked at the influence of a
series of differentially glycosylated IgG1-Fc mAbs with varying
glycan length generated through an enzymatic reaction on the
conformational stability (Mimura et al., 2000). Using DSC, gly-
cosylation length was found to play a role in IgG1 conformational
stability specifically in the CH2 domain where the N-linked gly-
cosylation site resides. In addition to influencing conformation,
glycosylation was found to have an effect on the protein’s suscep-
tibility to proteolysis. The existence of the glycan and the type of
terminal sugar in the glycan residue were reported to influence
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FIGURE 1 | Summary of step-wise nature of studies performed in a typical comparability assessment of a protein based drug candidate. Reproduced
from Federici et al. (2013) with permission from Elsevier.
the susceptibility of an IgG to papain digestion (Raju and Scallon,
2006, 2007).
Ensuring native-like higher order structure (secondary, ter-
tiary and quaternary structures) in a protein produced from
both pre- and post-change manufacturing processes is essen-
tial since the overall three dimensional configuration not only
defines a protein’s stability and functionality, but also its effi-
cacy and safety when being used as a therapeutic. Differences
in higher order structures could stem from physical changes in
structural integrity (i.e., partial unfolding, conformation changes
and aggregation) as well as from modifications in either the side
chains (mutation, deamidation) and/or PTMs such as glycosy-
lation. These differences in higher order structure (HOS) are
sometimes only detected during long-term storage or accelerated
storage which may involve changes to the surrounding environ-
ment (e.g., temperature shifts or agitation). In addition to the
properties of the protein molecule itself, pharmaceutical additives
(i.e., excipients such as salts, surfactants, sugars, etc.), solution
conditions (such as pH and ionic strength) as well as the nature of
the final dosage form (liquid vs. lyophilized) can also impact the
HOS of a protein.
The assessment of higher order structural integrity and
conformational stability of proteins in comparability studies
is best performed using multiple biophysical and calorimetric
techniques. Far-ultraviolet circular dichroism (CD) and Fourier
transform infrared spectroscopy (FTIR) have been widely used
to analyze the overall secondary structure content of proteins.
These methods produce distinctive signals that correspond to
the different secondary structural folds (i.e., α-helices and β-
sheets). Detailed studies regarding the use of CD spectra for
structural comparisons in comparability studies have been pub-
lished recently (Li et al., 2011; Teska et al., 2013). Common
techniques for the evaluation of the overall tertiary structure
of proteins are near UV absorbance measurements, fluorescence
spectroscopy and near-UV CD. Owing to the unique fluores-
cence and absorbance properties of aromatic amino acid residues
(tryptophan, tyrosine and phenylalanine) and their sensitivity to
the polarity of their local environment, changes in a protein’s
structural integrity and conformational stability upon partial or
full unfolding can be monitored. Furthermore, extrinsic fluores-
cence dyes (e.g., 1-anilino-8-naphthalenesulfonate, Sypro orange,
etc.) have been employed to monitor partially unfolded inter-
mediates (e.g., molten globular states) which have been often
shown to play a role in initiating protein aggregation events (Hari
et al., 2010; He et al., 2012; Sahin et al., 2012). Such dyes have
the valuable property of being relatively non-fluorescent in polar
environments (such as water) but become highly fluorescent in
less polar, more hydrophobic milieu such as protein interiors.
These features allow scientists to examine the onset of structural
unfolding of a protein as more apolar regions within a pro-
tein are exposed when a protein is stressed (e.g., during heating
or agitation). Differential scanning calorimetry (DSC), another
powerful analytical technique that can be used to monitor pro-
tein conformational stability, measures heat capacity differences
between the protein solution and a reference buffer as a func-
tion of temperature. As a protein’s structure begins to alter, heat
capacity increases resulting in an endothermic peak centered at
the thermal melting temperature (Tm, the midpoint of a protein
unfolding event). As part of a comparability study, DSC can also
provide information about the overall conformation stability of
the proteins under evaluation. Structural alterations in a protein
as a result of manufacturing process changes can be detected in
the form of a Tm shift or a change in the shape of the endothermic
peak. Multi-domain containing proteins (such as a monoclonal
antibody) show multiple endothermic peaks in a given DSC ther-
mogram. Structural changes in one of these domains can be
reflected in corresponding changes to the associated DSC peak
and further studied by deconvolution.
A limited number of case studies evaluating the effect of
changes in manufacturing processes on protein structure and
function from an analytical comparability perspective have been
published. In one study, the effects of changing the final dosage
form from a lyophilized formulation to a liquid dosage form, in
addition to the impact of transferring the bulk drug substance
to the commercial site, were evaluated for two monoclonal anti-
bodies (Lubiniecki et al., 2011). An increase in deamidation at a
www.frontiersin.org March 2014 | Volume 5 | Article 39 | 3
Alsenaidy et al. High throughput biophysical techniques for comparability studies
specific Asn site for one of thesemAbs was observed which did not
notably effect the structural integrity, biological potency or the
pharmacokinetic profile of the antibody in animal models. This
Asn deamidation was attributed to the transfer of the bulk pro-
cess to the commercial site at an increased scale which required
longer hold times in solution. Additional analytical evaluations
of the mAb’s conformational stability as well as functionality
using multiple analytical methods were performed, with no dif-
ferences observed between the two dosage forms of both mAbs.
The impact of changing formulation composition on protein
conformational stability has been addressed in a comparability
study (Cauchy and Hefford, 2010). In this work, the effect of
formulation exchange on a human growth hormone was evalu-
ated. The authors concluded that the formulation change affected
the structural integrity of the protein and additional considera-
tions needed to be given regarding the choice of final excipients.
Selecting an appropriate formulation for insulin was emphasized
in another study as they reported that changes observed on the
physical and chemical stability of insulin (due to changes in its
crystallization process) were dependent on the raw materials and
excipients used in formulation (DeFelippis and Larimore, 2006).
BIOLOGICAL ACTIVITY
Techniques used to characterize the biological activity of a pro-
tein serve as a critical complement to physiochemical assays
in confirming the correct higher order structure of a protein.
Determining bioactivity for monoclonal antibody based protein
drugs is usually done using a variety of in vitro binding assays
such as enzyme-linked immunosorbent assays (ELISA) and sur-
face plasmon resonance (SPR). Another group of bioassays, that
directly measures biological functionality, are often also used with
protein drugs including in vitro cell proliferation and in vivo
animal models. Using functionality bioassays (if feasible) in com-
parability studies is typically preferred over simple antigen bind-
ing assays because some degraded, modified protein molecules
could still bind non-specifically to the target molecule in a sim-
ple binding assay. Protein molecules containing multiple regions
with different functionalities should have multiple functional-
ity and/or binding bioassays reflecting each and every structural
region. For example, monoclonal antibodies are composed of
two antigen binding sites (Fab), responsible for antigen bind-
ing, and one crystallizable region (Fc), responsible for immune
effector functions. Each of these regions may need to be tested
for its ability to bind to its specified target to perform its desired
function.
Case studies examining protein functional activity changes due
to changes in manufacturing process have been reported. An
oxidized form of the protein filgratism (a human granulocyte-
colony stimulating factor used primarily for patients with severe
neutropenia) was found to lose 75% of its potency, whereas, fil-
gratism dimer had 67% potency compared to the intact molecule
(Cauchy and Hefford, 2010). In addition to influencing protein
conformation, glycosylation can play a critical role in defining
biological functionality. In the case of a mAb, the presence of a
core fucose unit in the N-linked oligosaccharide was found to
be responsible for decreasing the protein’s antibody-dependent
cellular cytotoxicity (ADCC). This highlights the importance of
glycan identification in comparability studies for pre- and post-
change mAb products (Shields et al., 2002). In another example,
TNK-Tissue Plasminogen Activator (TNK-tPA) is a glycosylated
protein which contains four glycosylation sites, three of which
are N-linked and the other O-linked. In a comparability study
(Jiang et al., 2010) of a biosimilar molecule under develop-
ment, the biosimilar protein had a similar glycosylation pattern
to the innovator drug product, except for one N-glycosylation site
which was found be only partially glycosylated. The close prox-
imity of the partially glycosylated glycan to the active site raised
concerns about its influence on the clot lysis biological activ-
ity, resulting in the need for more detailed studies to investigate
such effects. Another marketed protein product called Myozyme
(Alglucosidase alpha), used to treat patients with Pompe dis-
ease, that was produced at two different sites by the same com-
pany was found to be dissimilar in terms of biological activity
(Kozlowski et al., 2011). These differences in biological activ-
ity were attributed to glycosylation differences between proteins
from the two manufacturing sites.
ACCELERATED AND FORCED DEGRADATION STABILITY STUDIES
Forced degradation studies comprise a group of analytical tests
applied to the drug product to elucidate the physicochemical
mechanism(s) of protein degradation. Accelerated stability stud-
ies measure the rate of given degradation process over time at
various temperatures in specific formulations and primary con-
tainers. Evaluating the effect of storage period, excipients and
environmental stress on the accelerated (and long term) stability
of protein drug products is an essential part of formulation devel-
opment and comparability evaluations. Protein drugs encounter
different environmental stresses during production, storage, ship-
ment and patient administration. Thus, accelerated stability stud-
ies and forced degradation studies are needed to determine the
stability profile of a protein drug by subjecting the protein to
various stresses including elevated or changing temperatures,
freezing, thawing, agitation, oxidative environment, light, and the
presence of different interfaces and pH changes. (Britt et al., 2012;
Cordes et al., 2012; Miller et al., 2013; Wang et al., 2013a) The
design of successful forced degradation and accelerated stabil-
ity studies depends on having the appropriate analytical tools to
detect, quantify, and characterize any degradants, impurities and
side products generated during these studies.
Regulatory guidelines for stability studies that may be applied
to comparability assessments can be found in ICH Q3C (2003),
ICH Q5C (ICH Q3C, 1996) and ICH Q5E (2005). For example,
the ICH Q3C guideline mentions the importance of developing
analytical assays to quantify residual impurities of xylene leaching
from rubber stoppers during a freeze-drying process. Similarly,
the ICH Q5E guideline talks about divalent cations leaching from
vial stoppers which in turn activate trace amounts of proteases
leading to the degradation of a protein drug. Designing a suc-
cessful comparability stability study also depends on the type
of process or product change being evaluated. For instance, a
change in the final dosage form from a liquid to a lyophilized
drug product will generally result in a more stable product and
thus would not necessarily be expected to have a similar stability
profile. In this case, showing similarity of degradant type would
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be of primary interest. In an opposite scenario, changing from a
lyophilized dosage form to a liquid one, would not only require
evaluating the types of degradants but also testing the protein
drug product under additional stress conditions (e.g., mechani-
cal stress) to get additional insight into the aggregation behavior
of the liquid formulated protein drug.
Exposure to new surfaces from changing the primary contain-
ers or formulation additives has been reported to induce protein
aggregation and oxidation in some protein drug products. In one
study (Lubiniecki et al., 2011), an assessment of the impact of
changing the primary packaging from a vial to a pre-filled syringe
in terms of conformational integrity and stability of two mAbs
was evaluated. Similar molecular structure, biological activity and
degradation profiles were seen for both mAbs in a liquid formu-
lation filled in the vials and syringes with the one exception: a
small but statistically significant difference in subvisible particle
levels was noted and attributed to the presence of trace amounts
of silicon oil in the syringes. This has been reported to have
an undesirable effect on protein stability and aggregation (Jones
et al., 2005; Thirumangalathu et al., 2009). As a final example,
the biophysical stability of three lots of an IgG1mAb that were
manufactured and filled at different locations was assessed (Maity
et al., 2012). These three lots were incubated for multiple time
periods (0, 8, and 16 weeks) under either refrigeration (4◦C) or
heat stressed conditions (40◦C). No differences between the dif-
ferent lots of protein in terms of conformational stability as well
as in aggregation behavior were detected for the refrigerated lots.
In contrast, variations between the different lots stored at 40◦C
at different time points were seen using extrinsic (using ANS as a
dye) and intrinsic (Trp) fluorescence spectroscopy. Different lev-
els of aggregation were noted by static light scattering (SLS) and
size exclusion high performance liquid chromatography (SEC).
PHARMACOKINETIC STUDIES
In addition to the analytical comparability testing described
above, pharmacokinetic (pK) studies may need to be evaluated,
in the form of either non-clinical or clinical studies, in which
the pharmacokinetic profile of the protein drug is evaluated
using animal models (rodents or primates) or in humans, respec-
tively. In cases involving an observed non-similarity between the
products under comparison, it may be necessary to perform
pharmacokinetic studies in human subjects to demonstrate com-
parability (Putnam et al., 2010). These pharmacokinetic stud-
ies are performed using the same route of administration and
dose regimens providing comparative results (e.g., absorption,
bioavailability as well as elimination parameters like clearance
and elimination half-life) that should be highly similar for the
two samples being compared (Putnam et al., 2010). Changes
to a protein’s glycosylation pattern, charge distribution and
aggregation profiles upon manufacturing changes could have
a measurable effect on its pharmacokinetic profile, which may
or may not have an effect on the drug pharmacodynamics,
efficacy and safety profiles. The evaluation of such pK affects
are almost always carried out first using animal models (e.g.,
either rodents or primates), and if results are inconclusive,
human clinical pharmacokinetic comparability studies may be
necessary.
Glycosylation can play a central role in defining the circula-
tion and half-life in the human body for glycoproteins. In one
example, using a rat animal model, 50% loss in the amount of a
circulating protein (Ceruloplasmin, a copper carrying protein in
the blood) was observed after a 20% reduction in sialic acid con-
tent of the glycan attached to the protein (van den Hamer et al.,
1970). In some glycoproteins lacking sialic acid, it has been shown
that they have a higher affinity for mannose receptors in liver
cells, leading to a faster clearance and catabolism compared to the
fully sialylated ones (Stockert, 1995). The same fate was observed
for antibodies containing mannose terminated N-glycans (Kanda
et al., 2007; Goetze et al., 2011). Multiple comparability studies
have examined glycoproteins with different distributions of gly-
cosylation patterns due to a process change (especially cell-line
and cell culture changes). In one study, the amount of sialic acid,
in addition to the relative distribution of neutral oligosaccharides,
were different between the pre and post-change for mAb proteins
after changing the producing cells form a murine myeloma cell
line (NS0) to Chinese hamster ovary cells (CHO) (Kilgore et al.,
2008). Another study demonstrated that using a different clone
of the same cell line, or changing the cell culture components,
resulted in a significant increase in acidic glycoforms of a mAb
compared to the original cells (Lubiniecki et al., 2011).
Pharmacokinetic parameters have also been reported to be
sensitive to changes in the overall charge and aggregation state of a
protein drug. Proteins with specific charge heterogeneity profiles
have been shown, after modifying the manufacturing method,
to have a different charge distribution profile (He et al., 2009).
Changes in the overall charge state of a protein could alter the
electrostatic and hydrophobic interactions between the protein
and negatively charged cell membranes leading to a different
pharmacokinetic profile (Khawli et al., 2002). Using animal stud-
ies, minor shifts in the pI of a protein (in the range of 0.1-0.2 pI
units) have been demonstrated to have no effect on the pharma-
cokinetic profile (Harris, 2005). In contrast, shifts of above 1.0 pI
units may have a measurable effect. In one study, protein cation-
ization resulted in longer tissue retention times and a faster rate
of clearance (Hong et al., 1999). Protein anionization tended to
cause a decrease in tissue retention time but still increased whole
body clearance (Dellian et al., 2000) (demonstrated in rats and
mice, respectively). At the molecular level, changes in the charge
heterogeneity profile of a protein molecule could arise from alter-
ations in the primary sequence of the protein as a result of amino
acid mutations or chemical degradation (e.g., Asn deamidation)
(Sosic et al., 2008). Post-translational modifications (e.g., sialic
acid present on the glycan residues and C-terminal lysine) can
also contribute to the charge heterogeneity profile of a protein
(Sosic et al., 2008). Protein aggregation may affect pharmacoki-
netics profiles both directly or indirectly through the induction of
neutralizing antibodies. For example, insulin oligomers have been
reported to have a slower absorption and bioavailability upon
subcutaneous administration compared to non-aggregated form
of the protein (Pezron et al., 2002).
CLINICAL IMMUNOGENICITY STUDIES
Changes to the native structure of a protein could potentially
reveal or create new antigenic sites that could stimulate an
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immune response. An unwanted immune response against a
protein drug can be stimulated by many factors that are gener-
ally divided into two categories: extrinsic and intrinsic. Patient
immunogenic susceptibility and patient health status (admin-
istering co-medications) in addition to the dose and route of
administration are all considered extrinsic factors that may be
related to the immunogenicity of a protein based drug (Bal et al.,
2012). Intrinsic factors are those related to the protein or the
drug product itself including aggregation propensity, impurities
(e.g., residual host cell protein not removed by the purification
steps) and leachables (from container-closure systems, whichmay
or may not be immunogenic by themselves but could induce pro-
tein aggregation) (Ohkuri et al., 2010; Johnson and Jiskoot, 2012;
Rosenberg et al., 2012). The consequences of an immune reac-
tion against a protein drug could vary significantly, ranging from
clinically minor to severe, life-threatening effects. In one unfortu-
nate case, a specific erythropoietin-α drug product formulation
(Eprex®) was associated (in 1998 and peaked in occurrence in
2002) with pure red cell aplasia (PRCA) (Gershon et al., 2002). An
increase in neutralizing antibody titers in patients with chronic
renal failure against the protein drug was found, which was cor-
related with changes made to the product formulation (Boven
et al., 2005). Human serum albumin (HSA), used as a stabilizer,
was removed from the original formulation and substituted by
polysorbate 80 surfactant. The resulting instability has been ratio-
nalized in one report by the leaching of compounds (Seidl et al.,
2012) from the rubber plunger of the pre-filled syringe causing
the protein to unfold and aggregate. Another theory suggested
that polysorbate 80 formed micelles with the protein resulting in
an adjuvant-like nanoparticle that stimulated the immune sys-
tem (Schellekens, 2003). The route of administration can also
play a critical role in product immunogenicity. It was found
that patients who received Eprex® through an intravenous injec-
tion (IV) did not get PRCA unlike those that received the drug
subcutaneously (SC) (Schellekens, 2008).
Glycoproteins bearing different kinds of monosaccharides or
different linkages than the naturally occurring ones could poten-
tially stimulate the immune response as well. These glycan dif-
ferences are introduced by various mammalian cell lines used
to produce recombinant proteins. For example, the presence of
galactose-α-1, 3 glycans has been associated with anaphylactic
shock and an immune response in patients using cetuximab and
bovine thrombin, respectively (Schoenecker et al., 2000; Chung
et al., 2008). N-glycolylneuraminic acid (Neu5Gc or NGNA) is
a sialic acid glycan that contains an additional oxygen atom
compared to the naturally occurring N-acetylneuraminic acid
(Neu5AC or NANA) found in humans. The presence of this sialic
acid form (NGNA) has been associated with immunogenicity
risks (Hokke et al., 1990). A comparison between cetuximab and
panitumumab (both antibodies specific for binding epidermal
growth factor receptor), concerning the addition of Neu5Gc to
the glycan structure during expression in cell culture, showed
that cetuximab was only incorporating NGNA into the glycan
structure (Ghaderi et al., 2010). The addition of NANA to the
culture media helped reduce the incorporation of NGNA to the
glycoprotein drug. Finally, complete deglycosylation of a gly-
coprotein has been associated with an increasing incidence of
immunogenicity. Mechanisms underlying such an effect are not
fully understood, however, aggregation resulting from exposure
of normally hidden hydrophobic patches, decreasing solubility
and exposure of new antigenic sites (or a combination of factors)
has been proposed. For example, immunogenicity due to deglyco-
sylation was reported for interferon-β (Rudick et al., 1998; Runkel
et al., 1998)and granulocyte macrophage colony-stimulating fac-
tor (GM-CSF) (Gribben et al., 1990).
Protein aggregation is thought to have a significant impact on
the immunogenicity potential of protein drugs. Protein aggrega-
tion can be exacerbated by multiple factors including changes in
solution conditions (e.g., pH, salts, excipients, etc.) (Majumdar
et al., 2013; Manikwar et al., 2013; Wang et al., 2013a) and
exposure to various environmental stresses (e.g., temperature,
agitation, freeze-thaw, etc.) (Thirumangalathu et al., 2009; Cordes
et al., 2012; Sahin et al., 2012). An immunogenic response in
patients receiving an interferon alpha was attributed to the pres-
ence of aggregated species in the drug product, and was seen after
alterations in the formulation components (Braun et al., 1997).
A positive correlation between protein aggregation and immuno-
genicity has been shown as well for other therapeutic proteins,
such as insulin (Robbins et al., 1987), human growth hormone
(Moore and Leppert, 1980) and bovine serum albumin (Cleland
et al., 1993) confirming the important role of protein aggre-
gate detection and characterization in protein drug products.
(Wuchner et al., 2010; Jiskoot et al., 2012)
Immunogenicity prediction in humans using either in vitro
models or animal studies is difficult, and the development of
new approaches to obtain more reliable immunogenicity tests
remains highly desirable (van Mierlo et al., 2013). The need to
evaluate proteins after manufacturing changes for immunogenic-
ity becomes even more important for products with a past history
of immunogenicity (the pre-change product), as well for those
protein products with manufacturing changes that are considered
extensive (i.e., alteration of the cell line) or those that result in
observations of increased levels of aggregates or particles.
CURRENT ANALYTICAL CHALLENGES IN COMPARING PROTEIN
HIGHER-ORDER STRUCTURE
The type and extent of any comparability exercise depends on
the nature of the protein (size, complexity, and microheterogene-
ity), the magnitude and type of manufacturing changes, and the
analytical tools available to monitor the structural integrity of
a protein. An in-depth understanding of the protein including
its inherent susceptibility to the different chemical and physical
degradation mechanisms, combined with accumulated clinical
and manufacturing experience with a product, is essential for
a successful comparability study. Accurate structural determi-
nation for protein-based drugs is a difficult task for the phar-
maceutical and biotechnological industry, in contrast to small
molecule drugs, because of their complex three-dimensional
structures, sensitivity to their environment and their inherent
microheterogeneity. Major advances have been made in devel-
oping analytical tools for primary structure analysis, ranging
from chromatographic (size exclusion, reversed phase and ion-
exchange HPLC) and electrophoretic (capillary isoelectric focus-
ing and capillary sodium dodecyl sulfate) separation methods
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that are typically linked with mass spectrometry detection (intact
molecular weight, peptide maps, and oligosaccharides maps) to
accurately characterize a protein’s primary structure including
any post-translational modifications.
Physiochemical characterization of the higher-order structural
integrity of a protein when two slightly different but homolo-
gous drug products are being compared is one of the essential
elements of a comparability study. In fact, the current regulatory
expectation for performing functional biological potency assays
to ensure biological activity is considered a necessary check on
the higher order structural integrity of a protein. Although var-
ious lower resolution analytical techniques have been used and
developed to test higher order structural comparability between
two protein drugs (e.g., CD, fluorescence, and DSC as discussed
above), the use of higher resolution analytical techniques such as
NMR, X-ray crystallography, cryo EM and H/D exchange mass
spectrometry that provide structural details about a protein’s
folded structure and its dynamic behavior remains limited as part
of analytical comparability studies. Although these techniques
are very powerful in terms of obtaining detailed information
about a folded protein’s structure, their use has been restricted
due to some drawbacks including protein size and formulation
composition (presence of excipients) in addition to being tech-
nically challenging, expensive and time consuming techniques.
Research is currently being performed to overcome these draw-
backs. For example, the effect of different anions and excipients
on an IgG1mAb local flexibility was evaluated using H/DX-MS
(Majumdar et al., 2013; Manikwar et al., 2013). An increase in the
local flexibility of a certain peptide fragment in the CH2 domain
of the mAb was seen upon using thiocyanate (as an anion) and
arginine (as an excipient) that was correlated with decreased ther-
mal stability of the CH2 domain and an increase in aggregation
propensity. These results demonstrate the intricate interrelation-
ships between different excipients and their effect on protein
dynamics and physiochemical stability of a monoclonal antibody.
Recent advances in both H/DX-MS (Houde et al., 2011) and
NMR (Amezcua and Szabo, 2013) have shown promising poten-
tial in comparability studies, but have not yet reached the level of
routine use.
More well established, commonly available, lower resolution
biophysical techniques such as CD, intrinsic and extrinsic fluores-
cence spectroscopy, DSC, static light scattering and turbiditymea-
surements are widely used for the evaluation of secondary/tertiary
structure and colloidal stability of a protein within a pharma-
ceutical dosage form containing formulation components. These
biophysical methods can be setup as high throughput assays in
which analysis can be performed automatically across various
environmental conditions such as changes in solution pH and
temperature. Elevated temperatures and extreme pH conditions
are frequently used as stress factors to evaluate the overall confor-
mational sensitivity of proteins during formulation development,
but the use of these types of data sets for comparability analysis
has not yet been extensively explored. By using data sets acquired
from multiple low-resolution biophysical techniques that moni-
tor different aspects of a protein’s higher-order structural stability
as a function of environmental stress, differences in structural
integrity may potentially be detected when these differences are
not readily apparent when monitored using lower resolution
methods under non-stressed conditions (i.e., at low tempera-
tures under neutral pH conditions). Additionally, the evaluation
of conformational stability differences may not only be an effec-
tive surrogate to monitor differences in higher-order structure
between protein samples, but also a useful complement to tra-
ditional accelerated stability and forced degradation studies often
used in analytical comparability studies as described above.
HIGH THROUGHPUT BIOPHYSICAL METHODS AND DATA
VISUALIZATION TECHNIQUES
Although lower resolution biophysical techniques such as CD,
intrinsic/extrinsic fluorescence spectroscopy, DSC and static light
scattering measurements are commonly used to monitor the
structural stability of protein-based drugs, no single technique
provides sufficient information to establish the higher order
structural integrity of complex macromolecules such as proteins.
Therefore, the use of more than one technique is generally needed
for better characterization. The multi-dimensional nature of such
analysis makes collection, analysis and visualization of larger data
sets desirable. Historically, data analysis of protein conforma-
tional stability data was performed by either visual inspection or
data fitting of thermal unfolding curves to sigmoidal functions of
results from individual instruments. These types of approaches
can result in data interpretation that is not only subjective, but
limited in terms of their scope and utility.
In 2003, a new data visualization method was introduced as
a tool for analysis of protein physical stability data obtained from
high throughput biophysical measurements (Kueltzo et al., 2003).
This method known as the Empirical Phase Diagram (EPD), is a
data visualization tool that is based on using data sets from mul-
tiple low-resolution biophysical techniques to construct a color
coded diagram reflecting the different structural states that a pro-
tein would experience during at least two applied stress conditions
(e.g., pH, temperature, ionic strength, protein concentration,
etc.). Its application for formulation screening purposes for pro-
tein based drugs and vaccines has subsequently been extensively
evaluated (Maddux et al., 2011). The initial idea of developing
such a methodology stemmed from the fact that most compar-
ative experiments using protein thermal melting curves conven-
tionally use visual assessment and Tm/Tonset values to determine
differences between the different formulations under comparison.
This makes data interpretation across multiple samples diffi-
cult and potentially highly subjective. Using bovine granulocyte
colony stimulating factor (bGSCF) as a model protein com-
bined with second derivative absorbance spectroscopy as a model
biophysical method, the physical stability of the protein was char-
acterized across multiple pH and temperature conditions, and
the first EPD was constructed (Kueltzo et al., 2003). This EPD
was able to detect six different structural (non-thermodynamic)
phases that the protein experienced under a combination of the
stress variables of temperature and pH. By visual observation of
the individual data sets, these states were not easily detected.
An EPD analysis involves the collection of protein physical sta-
bility data under different experimental conditions usingmultiple
low-resolution biophysical techniques. The stability data from the
experimental conditions and techniques are then entered into
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m × n input matrix in which m represents the experimental
techniques (i.e., circular dichroism, fluorescence spectroscopy,
turbidity, etc.) and n represents the experimental conditions (i.e.,
number of pH values × number of temperature measurements).
After data normalization, singular value decomposition (SVD) of
the m × n experimental data matrix is calculated to extract three
orthogonal basis vectors associated with the three largest singular
values. These results are then mapped to red-green-blue (RGB)
color scheme that can be visualized as a function of the stress
conditions (e.g., temperature and pH). After an EPD is gener-
ated, what remains is the interpretation of the change of colors
of the different areas of the EPD. The colors of the different areas
within an EPD have no physical meaning. Instead, the change in
color signifies a structural change in the protein as detected by
the data from the individual experimental techniques. A scien-
tist must refer to the original experimental biophysical data and
consider the physical process that generated regions with differ-
ent colors for further interpretation of the molecular origin of the
color change.
The EPD method employs SVD and linear algebra to extract
distinctive patterns from a large collection of data. The EPD
method requires a number of steps as described in Figure 2. First,
the data must be extracted and stored from each instrument.
Second, the data should be preprocessed to correctly represent
macromolecular behavior. Care should be taken during pre-
processing, since each physical method may require different
types of pre-processing, and their results could directly impact
the output observed in the EPD. This preprocessing may include
buffer subtraction, smoothing, normalization, and peak picking.
For example, peaks are picked and traced from Trp fluores-
cence under various environmental conditions. Since the maxi-
mum peak position of Trp fluorescence is closely related to the
microenvironment around Trp residues, the peak position shift
often indicates conformational changes in the macromolecule.
Thus, the choice of peak picking algorithms, combined with
the subsequent functions described next, can impact the result-
ing EPD and its interpretation of the macromolecular behavior.
Third, preprocessed data should be organized into a matrix that
will then be used as an input to SVD. The rows of the input matrix
consist of samples under various environmental conditions. The
columns are results from the experimental techniques. Finally, the
three largest components from SVD results are selected and visu-
alized as a two-dimensional colored diagram. The three largest
components are the three left-singular vectors corresponding to
the three largest singular values. Each vector is mapped to RGB
colors; therefore, the combination of three produces a single
color for each sample condition. The final EPD can be obtained
by rearranging mapped colors along with two-dimensions of
environmental variables.
EPDs have been extensively used in formulation development
and stabilization studies with a wide variety of protein based
drugs and vaccines as reviewed in detail elsewhere (Maddux et al.,
2011). Since these EPD experiments have been carried out with
a wide variety of proteins, and with many different type of bio-
physical techniques, the opportunity for improvements in the
methodology have also been identified. For example, the use of
color as a means to display patterns inherently possesses several
disadvantages. The color itself in the EPD is automatically chosen;
therefore, there is no explicit and common relationship between
a color and the protein’s structural state. This produces difficul-
ties in interpretation of the EPD because the meaning of the color
cannot be directly used to analyze experimental data. In addition,
this method is difficult for people with vision color deficiencies.
To overcome these disadvantages, several new data visualization
FIGURE 2 | Typical procedure for collection of biophysical stability data sets and construction of Empirical Phase Diagram (EPDs), Three-Index EPDs,
and radar charts for data visualization and analysis.
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approaches (Kim et al., 2012; Iyer et al., 2013) have been recently
introduced.
First, instead of analyzing all experimental data together to
construct an EPD, each method used to determine secondary,
tertiary, and quaternary structural changes is analyzed separately
and mapped to a fixed color set. In this manner, a three-index
EPD can show structural changes in terms of defined colors. For
example, the color yellow is always used to display the native state.
The color blue is for the aggregated state and the color black
for the completely unfolded state without any aggregation. The
predefined colors enable intuitive analysis of not only a single,
but also a collection of three-index EPDs at the same time (e.g.,
comparison of mutants). This three-index EPD method can be
extended to visualize data from any three biophysical techniques,
if a proper color legend is provided.
Second, Radar charts and Chernoff face diagrams have been
utilized as color-free data visualization tools. They use certain
icons such as polygon axes and facial expressions, respectively, to
display large data sets under given conditions (Kim et al., 2012).
They can accommodate a larger number of different data sets
explicitly in a diagram compared to the original EPD method.
The major idea of radar charts is to arrange multiple axes, each
representing a different experimental technique, at evenly spaced
angles to form a polygon. Radar charts are composed of multi-
ple polygonal figures arranged in two dimensional coordinates
of environmental stress conditions (e.g., temperature and pH).
Each polygonal figure displays the experimental data from mul-
tiple instruments at the given stress conditions. Data from each
instrument can be normalized to have values between zero and
one. Then the value is mapped to a selected axis in the polar
coordinate where zero is assigned to the center of the circle
while one to the circumference. This mapping can be flipped
(e.g., zero to circumference and one to center) if it is neces-
sary to represent the native state of the protein as polygons with
the smallest area. In this manner, the structurally altered state
would be represented by polygons with larger area. Therefore,
the increasing polygonal area indicates transitions from the native
state to structurally altered states. Unlike EPDs, radar charts have
the advantage of displaying protein physical stability results from
a larger number of experimental techniques, allowing the evalu-
ation of protein structural integrity and conformational stability
over a wide range of methods and experimental conditions (Kim
et al., 2012).
The Chernoff face diagrams utilize facial expressions instead of
the polygons used with radar charts. Data sets from each instru-
ment are also normalized to have values between zero and one.
Then the value is mapped to a pre-defined facial feature such as
the angle of eye-brows, the size of eye pupil, and the angle of
mouth. These facial features are designed to express a variety of
parameters with distinctive and easily recognizable faces. The data
mapping can be adjusted to make the native state of the protein
have smiley faces. The structurally altered state may have other
facial expressions such as angry faces. Therefore, changes in facial
expression indicate structural transition. Although the Chernoff
face diagrams may not be appropriate to precisely visualize quan-
titative data as compared to radar charts or EPDs, they have
strengths to make communication with non-scientific audiences
more intuitive and easier (e.g., “In these conditions, the protein is
happy.”).
Finally, comparative signature diagrams (CSDs) (Iyer et al.,
2013) are designed to visualize statistically significant differ-
ences in biophysical stability data sets between two samples.
The mean and standard deviation of multiple datasets from
the same biophysical techniques for the two target samples
to be compared are calculated first for each variable such
as wavelength and temperature. The difference in means has
the limiting normal distribution as the number of datasets
approaches infinity. The threshold value such as three times
the standard deviation of mean difference is typically given
to decide statistically significant differences. Any mean differ-
ence within the threshold range will be discarded. Only sta-
tistically significant mean differences are plotted in the two
dimensional space as contour lines and colors, whose two axes
are the selected variables (e.g., wavelength, temperature, etc.).
Data from multiple biophysical techniques can be overlaid in
the same diagram by sharing the same temperature axis while
each technique-specific axis such as wavelength is normalized
accordingly.
CASE STUDIES USING DATA VISUALIZATION TECHNIQUES
TO COMPARE PROTEIN PHYSICAL STABILITY PROFILES
The case studies presented in this section exemplify the utility
of high throughput biophysical methods and data visualization
tools to characterize protein physical stability. In these case stud-
ies, the structural integrity of several model proteins such as acidic
fibroblast growth factor-1 (FGF-1), an IgG1 monoclonal anti-
body, and granulocyte colony stimulating factor (GCSF) were
characterized using various biophysical methods as a function of
temperature and solution pH. The large physical stability data
sets obtained were combined into various types of diagrams for
data visualization (Maddux et al., 2011; Kim et al., 2012; Iyer
et al., 2013). Examples include EPDs, radar charts and CSDs as
described above. The possible utility of these data visualization
tools in future analytical comparability studies is considered.
CASE STUDY: DIFFERENT MUTANTS OF ACIDIC FIBROBLAST GROWTH
FACTOR (FGF-1)
Alsenaidy et al. (2012) examined the utility of EPD based
approaches as an analytical tool to compare the conforma-
tional stability profiles of various acidic fibroblast growth factor-1
(FGF-1) mutants (Alsenaidy et al., 2012). The low intrinsic sta-
bility of FGF-1 has been identified as one of the key challenges
in the development of FGF-1 as a successful pro-angiogenic drug
candidate for the treatment of ischemic diseases and wound heal-
ing. Polyanion like heparin produce a substantial increase in the
physico-chemical stability and activity of FGF-1 by binding to
the native form of the protein (Mach et al., 1993; Tsai et al.,
1993). The addition of complex molecules like heparin, however,
is associated with additional complications such as enhanced cost,
immunogenicity and intrinsic pharmacological activity. As an
alternative, a mutation based approach directed toward enhanc-
ing the intrinsic stability of FGF-1 without adding exogenous
excipients was evaluated to reduce the dependency of FGF-1 on
heparin or other polyanions for stability and activity (Alsenaidy
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et al., 2012). A series of FGF-1 mutants were developed by mutat-
ing human FGF-1 to enhance its intrinsic stability and obtain
candidates with a stability profile similar to wild type (WT) FGF-1
in the presence of heparin. The thermodynamic stability and bio-
logical evaluation parameters reported in the literature for WT
andmultiple FGF-1mutants are summarized inTable 1. The EPD
evaluation for K12V/C117V/P134V (mutant H in Table 1) and its
comparison to WT-FGF-1 in the presence and absence of hep-
arin will be described in detail as an example. This mutant has
shown a significant increase in the thermostability (−G =
19.1 kJ/mol) and activity (EC50 = 1.80 ± 0.90 ng/mL) compared
to WT FGF-1 without heparin (Sample A in Table 1).
Both WT and mutant FGF-1 proteins were characterized as a
function of solution pH (3–8) and temperature (10–90◦C) using
various biophysical techniques. Far-ultraviolet circular dichroism
(far-UV CD) was used to characterize secondary (and tertiary)
structural changes in theWT andmutant FGF-1 at each pH value.
The CD signal at 228 nm, presumably reflecting a signal from
a combination of β-turns, loops and aromatic side chains, was
monitored as a function of temperature from 10 to 90◦C. Intrinsic
fluorescence measurements were carried out to monitor tertiary
structural changes. FGF-1 contains eight Tyr and one Trp and
the latter is quenched in the native state. Samples were excited at
280 nm and the ratio of fluorescence intensity at 305 and 330 nm
(I305/I330) was monitored as a function of temperature to reflect
the fluorescence signals from both Trp and Try residues. The
intensity at 305 nm was primarily due to Try residues whereas
330 nm corresponds to Trp residues. Because a single Trp residue
is quenched in the native conformation of FGF-1, higher values of
I305/I330indicate native like structure whereas low values reflect an
altered conformation. Extrinsic fluorescence measurements using
1-Anilino-8-naphthalnesulfonate (ANS) were also performed to
monitor the exposure of apolar sites as an indicator of conforma-
tional alteration in the protein. ANS fluorescence intensity was
measured at 480 nm as a function of temperature. Aggregation
behavior of the protein at different pH values was evaluated
by measuring static light scattering at 280 nm as a function of
temperature.
The large data sets obtained from all the techniques for each
pH value from 3 to 8 were summarized into an EPD. Two dis-
tinct regions were observed in the EPD for WT-FGF-1 without
heparin (Figure 3A). The green area (region 1) comprises neutral
pH (∼4.5–8) and low temperature (∼10–40◦C) and presumably
reflects a more stable, native-like state of the protein. The blue
area (region 2) reflects a conformationally altered and/or aggre-
gated state. A structure transition was observed in the region
between pH 6 and 7 at ∼44◦C. A third region manifested as
a light blue region between the boundaries of region 1 and
2 was also present but wasn’t well resolved. This region sug-
gests the presence of a molten globule (MG)-like state (near




Symbol G (kJ/mol) EC50 (ng/mL)(−) heparin EC50 (ng/mL) (+) heparin Half-life (h) Heparin binding
Group I
WT (without and with
heparin)
A and B - 58.4±25.4 0.48± 0.08 1.0 Yes
L26D/H93G (Lee et al.,
2008)
C −0.9 N.A. N.A. N.A. Yes
C83T/C117V/K12V (Lee
and Blaber, 2009a)
D −1.9 0.93±0.25 0.36± 0.12 40.4 Yes
P134V/C117V (Dubey
et al., 2007)
E −8.8 46.8±6.7 N.A. N.A. Yes
K12V/C117V (Dubey
et al., 2007)
F −9.3 4.2±1.7 N.A. N.A. Yes
A66C (oxi) (Lee and
Blaber, 2009b, 2010)
G −10.2 5.43±3.96 0.36± 0.20 14.2 Yes
K12V/C117V/P134V
(Dubey et al., 2007)
H −19.1 1.80±0.90 N.A. N.A. Yes
GROUP II
C83T/C117V/L44F/F132W
(Lee and Blaber, 2009a)
I −0.4 0.74±0.19 0.51± 0.15 42.6 Yes
SYM6/K12V/P134V
(Lee et al., 2011)
J −35.0 741±302 N.A. N.A. No
Symfoil-4P (Lee and
Blaber, 2011)
K −44.1 N.A. N.A. N.A. No
SYM10 (Lee et al.,
2011)
L −47.0 N.D. N.A. N.A. No
See indicated references for values of individual mutants. Reproduced from Alsenaidy et al. (2012) with permission from John Wiley and Sons.
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FIGURE 3 | Empirical Phase Diagrams (EPDs) for comparative analysis of
conformational stability of FGF-1 and its mutant. The EPDs were
developed for wildtype FGF-1 (A), wildtype FGF-1 with heparin (B) and
K12V/C117V/P134V mutant of FGF-1 (no heparin) (C). Stability data as function
of pH and temperature were collected from the following methods: intrinsic
fluorescence intensity ratio at two wavelengths (I305/I330 nm), CD at 228 nm,
static light scattering (SLS) and ANS fluorescence intensity. Reproduced from
Alsenaidy et al. (2012) with permission from John Wiley and Sons.
native secondary structure, altered tertiary structure). As shown
in Figure 3B, in the presence of heparin, an apparent bound-
ary for region 1 (green area) shifts toward a higher temperature
region. The area covered by region 2 (blue area) decreased and
a third region (pink area), reflecting the presence of an MG-
like state become more prominent. The structural transitions
from native to altered conformations are observed at ∼60◦C
which is ∼16◦C higher than the WT FGF-1 in the absence of
heparin. A comparison between two EPDs for FGF-1 without
(Figure 3A) and with heparin (Figure 3B) showed differences in
various states of the protein. The native like state as reflected by
region 1 (green area) is more prominent in the FGF-1 with hep-
arin (Figure 3B). The altered conformation/aggregated state is
also less evident and a higher structural transition temperature
is observed for FGF-1 with heparin. This comparison suggests a
better stability of FGF-1 in the presence of heparin than with-
out heparin and is in agreement with the parameters shown in
Table 1.
The EPD for K12V/C117V/P134V (mutant H inTable 1) again
showed two regions, region 1 (green area) and region 2 (blue
area) reflecting native-like and an altered/aggregated state of the
protein, respectively (see Figure 3C). The area encompassing the
native-like state (region 1) is more expanded than in the EPD
for WT FGF-1 without heparin (Figure 3A). This result indi-
cates the better stability of the mutant in the absence of heparin.
The structural transition temperature is also observed at 52◦C
which is∼8◦C higher than theWT FGF-1 without heparin. Taken
together with the parameters in Table 1, comparative EPD analy-
sis confirms that the mutant protein is in a stable and bioactive
conformation that does not rely on presence of heparin. This
study provides evidence that the EPD methodology can be a use-
ful analytical tool in comparing the global physical stability profile
of different FGF-1 mutants.
CASE STUDY: DIFFERENT IgG1mAb GLYCOFORMS DUE TO
DEGLYCOSYLATION
This second case study illustrates the applicability of a com-
bination of data visualization techniques including EPDs and
radar plots to the evaluation of the conformational stability
profiles of different glycoforms of an IgG1 monoclonal antibody.
The glycosylation pattern of monoclonal antibodies can play an
important role their functionality and clearance from the body
(Arnold et al., 2007), and can influence conformational stabil-
ity and solubility (?Krapp et al., 2003; Wacker et al., 2011). In
this study, Alsenaidy et al. (2013) evaluated changes in the struc-
tural and conformational integrity of various glycoforms of an
IgG1mAb generated by enzymatic deglycosylation to obtain par-
tially and fully deglycosylated forms (Alsenaidy et al., 2013).
A two-step method was adopted in this work to monitor the
structural and conformational changes in the mAb glycoforms
as function of solution pH and temperature. In the first step,
the EPDs were generated over a wide range of solution condi-
tions with a variety of analytical techniques. In the second step,
a narrower temperature and pH range was selected along with
employment of the most sensitive analytical techniques. A pH
range of 4.0–6.0 with 0.5 increments was selected based on the
initial, step-one experiments with completely glycosylated and
deglycosylated mAbs. The techniques used to monitor changes in
different structural and conformational features included far-UV
CD for secondary structure, intrinsic tryptophan and extrinsic
ANS/Sypro Orange fluorescence spectroscopy for tertiary struc-
ture, static light scattering for aggregation and DSC for overall
structural stability. The physical stability data sets obtained from
the different techniques were summarized into EPDs and radar
charts for analysis and comparison of conformational stability
profiles.
As shown in Figure 4 (left panel), EPDs for the untreated,
native mAb (control) (Figure 4A), partially deglycosylated
(Figure 4B) and completely deglycosylated (Figure 4C) mAb
were generated. The blue and green colors in the EPDs reflect
regions where the IgG1mAb is in a native-like and structurally
alerted state, respectively. A third region of varying colors and
intensity signifies aggregation or precipitation of the IgG1 gly-
coforms. The conformational stability can be compared among
different IgG1 glycoforms using EPDs by comparing the location
of the boundaries and area encompassed by the different color
regions. Comparing blue regions which reflect the appearance
of the native state of the protein across different EPDs, at pH
5.5 and 6, the structural transition temperature was 64◦C in the
case of untreated mAb (Figure 4A) and partially deglycosylated
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FIGURE 4 | Analysis of the conformational stability of IgG1mAb
glycoforms using Empirical phase diagrams (left panel) and Radar
charts (right panel). The diagrams show conformation stability of fully
glycosylated (control) (A), partially deglycosylated (B) and fully
deglycosylated (C) IgG1mAb. Stability data as function of pH and
temperature were collected from the following methods:
differential scanning calorimetry, differential scanning fluorimetry, ANS
fluorescence intensity and static light scattering.
Reproduced from Alsenaidy et al. (2013) with permission from John
Wiley and Sons.
IgG1 (Figure 4B) whereas a value of 59◦C was obtained for the
completely deglycosylated form (Figure 4C). At pH 5.0, transi-
tion temperatures changed to 63 and 61◦C for native and partially
deglycosylated forms, respectively. At this pH, the EPD for the
completely deglycosylated IgG1 showed additional color regions
suggesting the presence of multiple conformationally altered
states of the protein. The structural transition temperatures were
further lowered to 50 and 55◦C for untreated IgG1 at pH 4.0 and
4.5, respectively. At these pH values, the partially deglycosylated
(Figure 4B) and fully deglycosylated (Figure 4C) forms showed
Frontiers in Pharmacology | Pharmaceutical Medicine and Outcomes Research March 2014 | Volume 5 | Article 39 | 12
Alsenaidy et al. High throughput biophysical techniques for comparability studies
additional colored regions reflecting different conformationally
altered sates of these glycoforms. The presence of additional green
region in fully deglycosylated mAb (Figure 4C) at pH 4 sug-
gests more extensive structural/ conformational alterations even
at lower temperatures.
Radar plots were also constructed (Figure 4, right panel) using
the same biophysical stability data set used for the construction of
the color EPDs. The structural transitions were obtained by using
a k-Means clustering algorithm to identify the apparent phase
boundaries as described in the previous section. Under the similar
pH and temperature range used for the EPDs, similar regions of
conformation and structure were identified in the radar plots. The
region of native-like conformation/structure was 67, 52, and 40%
for untreated, partially deglycosylated, and fully deglycosylated
forms of the mAb, respectively. These results demonstrate that
the physical stability profile (i.e., EPD and radar chart diagrams
of pH vs. temperature) of this IgG1mAb changed as a function of
varying its glycosylation pattern in a pH dependent manner.
CASE STUDY: DIFFERENT FORMULATIONS OF GRANULOCYTE COLONY
STIMULATING FACTOR (GCSF)
The third case study describes an alternative data visualization
tool that involves a more rigorous mathematical treatment of the
biophysical data to carry out a statistical comparison for com-
parability studies (Iyer et al., 2013). The CSDs were proposed
as a way to measure the statistical significant difference among
different sets of spectral data generated from various biophysical
instruments used for protein structure/conformation characteri-
zation. This study illustrates construction of CSDs for the protein
Granulocyte Colony Stimulating Factor (GCSF) in 16 different
formulations. The protein formulations were characterized using
far-UV CD, Trp intrinsic fluorescence, ANS extrinsic fluorescence
and static light scattering, and the data as a function of pH and
temperature were obtained for the construction of CSDs.
These CSD diagrams incorporate the entire spectrum and
any significant differences between data sets are represented as
colored regions. The x and y axis in CSDs represent different
arbitrary values to signify the data from different techniques and
formulation variables. As shown in Figure 5, CSDs were con-
structed for 16 different GCSF formulations listed in the Table 2.
These diagrams were constructed at the 75th quartile using a
difference of five standard deviations to show significant differ-
ences which are illustrated by various colors. Differences in CD
spectra (200–260 nm) are represented by green color, intrinsic
Trp fluorescence (300–400 nm) by blue color, and extrinsic ANS
fluorescence (400–600 nm) by red color. The side bar reflects
the differences seen in the aggregation behavior. The solid out-
line represents positive differences whereas dashed outline shows
negative ones.
As shown in Figure 5, a comparative analysis of the different
GCSF formulations compared to a control formulation (GCSF
012 in Table 2) is presented. For the current discussion, only
Figure 5A (formulation GCSF 011minus GCSF 012) is described
in detail. The differences in CD spectra (secondary structure)
as depicted by green color were seen at ∼215–230 nm where
GCSF 12 shows relatively larger changes in secondary structure
above 60◦C. The tertiary structural changes as illustrated by the
blue color were seen in different temperatures regions. In 300–
325 and 350–375 nm regions of the spectra at ∼40–45◦C, light
blue colored regions reflect minor conformational differences of
the protein in the two formulations. The strong blue color in
the ∼300–310 nm range at above 70◦C reflects the higher aggre-
gation propensity of the protein in the GCSF 011 formulation.
This effect is supported by a strong negative difference in the
light scattering data between the two formulations as represented
by the side bar with dotted outline in Figure 5. Finally, the red
color in the lower temperature range shows the differences in ANS
fluorescence in the two protein formulations. This fluorescence
difference was suspected to be due to ANS bound to polysorbate-
80 which was present at a high concentration (0.05%) in GCSF
011. The red color in higher temperature regions reflects the
enhanced binding of ANS to the protein in control formulation.
As a control, Figure 5B depicts a CSD diagram comparing the
same formulation to itself. The absence of colored regions shows
the internal consistency of method.
Looking across the various formulations in Figure 5,
Formulation GCSF 019 (Figure 5I) and GCSF 020 (Figure 5J)
showed the least differences whereas GCSF 24 (Figure 5N),
GCSF 25 (Figure 5O) and GCSF 26 (Figure 5P) reflects the
largest differences in structures/conformation based on the CSD
analysis. This technique shows its potential to detect significant
differences in protein spectra among different formulations
under varying conditions of pH and temperature. Further work
using different analytical techniques and additional proteins,
however, is required to better establish the use of CSDs in
analytical comparability studies.
CASE STUDY: DIFFERENT AGGREGATION PROFILES FOR AN IgG1mAb
The comparisons of impurity profiles between samples can be
another important aspect of comparability assessments. One key
product related impurity is the formation of aggregates and
particles in protein formulations during storage (Wang, 2005;
Hamada et al., 2009; Wuchner et al., 2010). A careful analysis
of particle/aggregate profiles can be an important component of
comparability studies where changing the pharmaceutical dosage
form during development can lead to changes in the formation
of these unwanted species (Lubiniecki et al., 2011; Federici et al.,
2013). Evaluation of the effects of various stress and solution
conditions and excipients on particle/aggregate formation, how-
ever, remains challenging due to lack of suitable analytical tools
for comprehensive analysis of a large amount of data generated
by various methods used in particle size characterization (Wang
et al., 2013b).
In this case study, Kalonia et al. (2013) have evaluated radar
charts as a novel data visualization tool to compare aggregate and
particle formation profiles for an IgG1 monoclonal antibody in
different formulations upon subjecting to different stress con-
ditions. Effects of various solution parameters such as pH and
NaCl concentration on size, concentration, kinetics and mor-
phology of subvisible IgG mAb particle formation after shaking,
stirring and heating were analyzed byMicro Flow Imaging (MFI).
MFI is a digital imaging technology that generates tens to hun-
dreds of thousands of images of protein particles in solution.
These large data sets can be difficult to analyze, and in this work,
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FIGURE 5 | Comparative Signature Diagrams (CSDs) for different
formulations of Granulocyte Colony Stimulating Factor (GCSF).
Formulation GCSF 12 was used as the control condition. Each diagram
(A–P) represents the comparison of a particular formulation with GCSF
12. Red, blue, and green colors represent differences in spectra of ANS
fluorescence, intrinsic fluorescence and CD, respectively. The side bars
represent differences in aggregation pattern. The solid outline indicates
positive differences and dashed outline negative differences.
Reproduced from Iyer et al. (2013) with permission from John Wiley and
Sons.
data generated by MFI was incorporated into radar chart arrays
to better assess and compare the size, number and morphology
of protein particles formed in different formulations exposed to
different stress conditions.
As shown in Figure 6, a series of radar charts were gener-
ated to compare the effect of two different stress conditions and
a varying amount of NaCl on the size and number of IgG1
subvisible particles formed (Figure 6A) and the morphology
of these particles (Figure 6B). Unstressed mAb samples show
approximately 100–3000 subvisible particle across the different
salt concentrations (Figure 6A, upper panel). Shaking and stir-
ring of samples for 240min resulted in the formation of a large
amount of particles of varying number and size (Figure 6A,
lower panel). Particles of larger size (25–50 and 50–70μm)
were formed in the samples subjected to shaking stress com-
pared to stirred samples (particle size primarily in the 2–25μm
range). The formation of particles/aggregates was significantly
influenced by the concentration of salt. For example, after stirring
for 240min, samples without salt showed less than 50,000 par-
ticles/ml whereas 300,000 and >106 particles/ml of 2–5μm size
Frontiers in Pharmacology | Pharmaceutical Medicine and Outcomes Research March 2014 | Volume 5 | Article 39 | 14
Alsenaidy et al. High throughput biophysical techniques for comparability studies
FIGURE 6 | Radar chart analysis of subvisible particles in IgG1mAb
solution after stirring and shaking stresses in the presence of varying
amount of sodium chloride. The size and number (A) and morphology (B) of
subvisible particles were measured by Micro Flow Imaging (MFI). Each axis in
an individual radar chart represents particles of various size ranges (clockwise
from top: 2–5, 5–10, 10–25, 25–50 and 50–70μm). Each ring positioned from
the center to periphery displays in (A) 10 fold increase in particle concentration
from <10 (center) to > 106 (edge) particles/ml, and in (B) 0.1 increments in
morphological parameters (aspect ratio or intensity/1000) from <0.35 (center)
to >0.85 (edge). The outer polygons showmean values whereas inner
polygons represent mean minus 1SD (standard deviation) in (A) and mean plus
1SD in (B). The light red shaded regions in (B) represent areas with insufficient
number of particles to report results (less than 25). Reproduced from Kalonia
et al. (2013) with permission from JohnWiley and Sons.
Table 2 | Composition of different formulations containing the protein
granulocyte colony stimulating factor (GCSF).
Formulation Buffer Buffer pH Excipient Excipient
concentration concentration
(mM) (%)
GCSF011 No No 4.5 Tween-80 0.05
GCSF012 No No 4.5 Tween-80 0.005
GCSF013 No No 5 Tween-80 0.005
GCSF014 No No 5 Tween-80 0.05
GCSF015 Citrate 20 4.5 Tween-80 0.005
GCSF016 Citrate 50 4.5 Tween-80 0.05
GCSF017 Citrate 20 5 Tween-80 0.05
GCSF018 Citrate 50 5 Tween-80 0.005
GCSF019 No No 4 HPBCD 5
GCSF020 No No 4 HPBCD 1
GCSF021 No No 4.5 HPBCD 1
GCSF022 No No 4.5 HPBCD 5
GCSF023 Acetate 20 4 HPBCD 1
GCSF024 Acetate 100 4 HPBCD 5
GCSF025 Acetate 20 4.5 HPBCD 5
GCSF026 Acetate 100 4.5 HPBCD 1
The physical stability of GCSF in the different formulations was measured by
multiple biophysical methods and results compared using comparative signature
diagrams (CSDs) as shown in Figure 5 Reproduced from Iyer et al. (2013) with
permission from John Wiley and Sons.
HPBCD, Hydroxypropyl Beta Cyclodextrin.
range were observed in the presence of 0.15M and 1M NaCl,
respectively. One important feature of the radar charts is that
they include the statistical variability in the data as shown in the
shaded regions in Figure 6A.
Radar charts were also constructed for morphology analysis
of subvisible IgG1 particles formed under the above mentioned
solution and stress conditions. As shown in Figure 6B, the average
particle aspect ratio (a measure of particle elongation) and inten-
sity (a measure particle transparency) remained constant upon
stirring for 240min across the different salt concentrations. In
the case of shaking for 240min, the average aspect ratio of par-
ticles decreased in the presence of 1M salt. An average aspect
ratio of less than 0.35 was calculated for subvisible particles larger
than 25μm indicating the formation of fiber-like particles under
these conditions. Compared to no salt or 0.15M salt samples, an
increase in intensity of the particles in the size range of 25–50μm
was observed in mAb samples shaken in the presence of 1M salt
(Figure 6B).
Radar charts were also prepared for analysis of data from mul-
tiple particle sizing/counting instruments which cover a wider
range of mAb particle sizes. Size exclusion chromatography
(SEC) was used to measure soluble aggregates, resonance mass
measurements (RMM) to measure sub-micron particles (∼0.3–
2μm) and MFI to measure sub-visible particles (2–70μm).
These “multiple-instrument radar charts” were prepared for the
heat and stirring induced aggregation of the mAb under vary-
ing salt concentrations and the mechanistic basis and kinet-
ics of aggregates/particles formation was evaluated. Such types
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of data presentation further diversify the applicability of the
radar chart based data visualization technique in comprehensive
characterization of different sizes of aggregates/particles in
various formulations under a variety of stress conditions.
This case study illustrates the capability of using radar charts
to summarize and compare large data sets from MFI analysis of
particle size distribution, concentration, and morphology across
different protein formulations in a single figure. This work also
demonstrates the potential utility of radar chart analysis to com-
pare the profiles of aggregate and particle formation of varying
size ranges and morphologies as measured by a variety of ana-
lytical methods, across different protein samples in analytical
comparability assessments.
SUMMARY
The analysis of protein higher-order structure is an essential
part of analytical comparability assessments of biopharmaceu-
tical drug candidates. Although there are a number of higher
resolution analytical tools potentially available to examine and
compare the higher-order structure of protein molecules, many
of these techniques have practical limitations in their routine use
including technical complexities, low-throughput, high costs and
difficult interpretability. Additionally, the size and concentration
of a protein as well as the presence of various additives in the for-
mulation (which can interfere with some of these assays) further
restrict their use. While lower resolution biophysical techniques
are more readily available to analyze various structural aspects of
protein molecules in pharmaceutical formulations, such methods
may be unable to detect minor structural alterations in protein
molecules even if they have significant implications for their func-
tionality. In this review, we have illustrated that the biophysical
characterization of various protein molecules (subjected to dif-
ferent environmental stresses, e.g., solution conditions, pH, tem-
perature, agitation), by using a combination of lower resolution,
high-throughput techniques combined with various data visual-
ization tools, can detect physical stability differences in proteins
with minor structural/conformational changes. The case stud-
ies of FGF-1 mutants and differentially glycosylated IgG-1mAbs
demonstrated the application of this approach to compare the
effect of relatively minor modifications in protein structure on
their conformational stability. The GCSF case study illustrated
a data visualization technique to statistically compare the struc-
tural/conformational stability differencesmeasured with the same
protein in different formulations. The final case study presented a
radar chart data visualization technique to more comprehensively
characterize protein aggregate and particle formation as gener-
ated by two different agitation stresses applied to IgG1mAb solu-
tions containing varying levels of sodium chloride. In conclusion,
characterization of the physical stability of proteins using vari-
ous lower resolution, higher throughput biophysical techniques,
combined with different environmental stresses and data visual-
ization tools, can potentially as serve as a useful tool to evaluate
the higher-order structural integrity of proteins for comparability
purposes.
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